Individuals with Mast Cell Activation Syndrome (MCAS), a rare chronic disease, experience unpredictable physical symptoms and diagnostic challenges resulting in poor emotional states. The prevalence and correlates of depressive symptoms were examined among 125 participants who completed the CES-D and relevant instruments. The majority reported a clinically-significant level of depression which was especially common among younger participants and those who reported greater loneliness or more disease-specific stressors. Greater magnitude of depressive symptoms was associated with greater illness intrusiveness, less social support, and lower optimism. Results highlight the value of interventions targeting loneliness and stressors unique to this population.
AkinC (2014) Mast cell activation disorders. The Journal of Allergy and Clinical Immunology: In Practice2: 252–257.
2.
AkinCValentPMetcalfeDD (2010) Mast cell activation syndrome: Proposed diagnostic criteria. Journal of Allergy and Clinical Immunology126(6): 1099–1104.e4.
3.
ÅsbringPNärvänenA-L (2002) Women’s experiences of stigma in relation to chronic fatigue syndrome and fibromyalgia. Qualitative Health Research12: 148–160.
4.
BarlowJHCullenLARoweI (2002a) Educational preferences, psychological well-being and self-efficacy among people with rheumatoid arthritis. Patient Education and Counseling46: 11–19.
5.
BarnwellAMKavanaghDJ (1997) Prediction of psychological adjustment to multiple sclerosis. Social Science & Medicine45: 411–418.
6.
BauerLCaroMBeachSR, et al. (2012) Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. The American Journal of Cardiology109: 1266–1271.
7.
BessahaMLSabbathELMorrisZ, et al. (2020) A systematic review of loneliness interventions among non-elderly adults. Clinical Social Work Journal48(1): 110–125.
8.
BoddaertNSalvadorAChandesrisM, et al. (2017) Neuroimaging evidence of brain abnormalities in mastocytosis. Translational Psychiatry7: e1197.
9.
BolgerNDavisARafaeliE (2003) Diary methods: Capturing life as it is lived. Annual Review of Psychology54: 579–616.
10.
ButterfieldJH (2006) Systemic mastocytosis: Clinical manifestations and differential diagnosis. Immunology and Allergy Clinics of North America26(3): 487–513.
11.
CacioppoJTHawkleyLCCrawfordLE, et al. (2002) Loneliness and health: Potential mechanisms. Psychosomatic Medicine64(3): 407–417.
12.
CacioppoJTHughesMEWaiteLJ, et al. (2006) Loneliness as a specific risk factor for depressive symptoms: Cross-sectional and longitudinal analyses. Psychology and Aging21(1): 140–151.
13.
CardetJCCastellsMCHamiltonMJ (2013) Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Current Allergy and Asthma Reports13: 10–18.
14.
CarverCSPozoCHarrisSD, et al. (1993) How coping mediates the effect of optimism on distress: A study of women with early stage breast cancer. Journal of Personality and Social Psychology65(2): 375–390.
CohenSJanicki-DevertsDMillerGE (2007) Psychological stress and disease. JAMA298(14): 1685–1687.
17.
CorriganPWPennDL (1999) Lessons from social psychology on discrediting psychiatric stigma. American Psychologist54(9): 765–776.
18.
CorriganPWWatsonACBarrL (2006) The self–stigma of mental illness: Implications for self–esteem and self–efficacy. Journal of Social and Clinical Psychology25(8): 875–884.
19.
DehnaviSRHeidarianFAshtariF, et al. (2015) Psychological well-being in people with multiple sclerosis in an Iranian population. Journal of Research in Medical Science: The Official Journal of Isfahan University of Medical Sciences20(6): 535–539.
20.
DevinsGM (1994) Illness intrusiveness and the psychosocial impact of lifestyle disruptions in chronic life-threatening disease. Advancement in Renal Replacement Therapy1: 251–263.
21.
DevinsGMBinikYMHutchinsonTA, et al. (1984) The emotional impact of end-stage renal disease: Importance of patients’ perceptions of intrusiveness and control. The International Journal of Psychiatry in Medicine13: 327–343.
22.
DiMatteoMRLepperHSCroghanTW (2000) Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Archives of Internal Medicine160: 2101–2107.
23.
FeltonBJRevensonTA (1984) Coping with chronic illness: a study of illness controllability and the influence of coping strategies on psychological adjustment. Journal of Consulting and Clinical Psychology52(3): 343–353.
24.
FindleyJCKernsRWeinbergLD, et al. (1998) Self-efficacy as a psychological moderator of chronic fatigue syndrome. Journal of Behavioral Medicine21: 351–362.
25.
FisherLSkaffMMMullanJT, et al. (2007) Clinical depression versus distress among patients with type 2 diabetes: Not just a question of semantics. Diabetes Care30(3): 542–548.
26.
GeisserMERothRSRobinsonME (1997) Assessing depression among persons with chronic pain using the Center for Epidemiological Studies-Depression Scale and the Beck Depression Inventory: a comparative analysis. Clinical Journal of Pain13(2): 163–170.
27.
Georgin-LavialleSMouraDSBruneauJ, et al. (2014) Leukocyte telomere length in mastocytosis: Correlations with depression and perceived stress. Brain, Behavior, and Immunity35: 51–57.
28.
Georgin-LavialleSMouraDSSalvadorA, et al. (2016) Mast cells’ involvement in inflammation pathways linked to depression: Evidence in mastocytosis. Molecular Psychiatry21: 1511–1516.
29.
GoudsmitEStoutenBHowesS. (2009) Illness intrusiveness in myalgic encephalomyelitis: An exploratory study. Journal of Health Psychology14: 215–221.
30.
Graham-EngelandJESinNLSmythJM, et al. (2018) Negative and positive affect as predictors of inflammation: Timing matters. Brain, Behavior, and Immunity74: 222–230.
31.
HamiltonMJHornickJLAkinC, et al. (2011) Mast cell activation syndrome: A newly recognized disorder with systemic clinical manifestations. Journal of Allergy and Clinical Immunology128: 147–152.e142.
32.
HawkleyLCCacioppoJT (2010) Loneliness matters: A theoretical and empirical review of consequences and mechanisms. Annals of Behavioral Medicine40(2): 218–227.
33.
HeemstraHEvan WeelySBüllerHA, et al. (2009) Translation of rare disease research into orphan drug development: disease matters. Drug Discovery Today14(23–24): 1166–1173.
34.
HermineOLortholaryOLeventhalPSet al. (2008) Case-control cohort study of patients’ perceptions of disability in mastocytosis. PloS One3(5): e2266.
35.
HughesMEWaiteLJHawkleyLC, et al. (2004) A short scale for measuring loneliness in large surveys: Results from two population-based studies. Research on Aging26: 655–672.
36.
IBM Corp (2017) IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp.
37.
JacobyAAustinJK (2007) Social stigma for adults and children with epilepsy. Epilepsia48: 6–9.
38.
JenningsSRussellNJenningsB, et al. (2014) The Mastocytosis Society survey on mast cell disorders: Patient experiences and perceptions. The Journal of Allergy and Clinical Immunology: In Practice2: 70–76.
39.
JenningsSVSleeVMZackRM, et al. (2018) Patient perceptions in mast cell disorders. Immunology and Allergy Clinics38: 505–525.
40.
KaneS (2007) Just a spoonful of sugar helps the medicine go down. . . If only it was that simple! Nonadherence in inflammatory bowel disease. American Journal of Gastroenterology102(7): 1427–1428.
41.
Kiecolt-GlaserJKDerryHMFagundesCP (2015) Inflammation: Depression fans the flames and feasts on the heat. American Journal of Psychiatry172(11): 1075–1091.
42.
LittermanNKRheeMSwinneyDC, et al. (2014) Collaboration for rare disease drug discovery research. F1000Research3: 261.
43.
LorigKRSobelDSRitterPL, et al. (2001) Effect of a self-management program on patients with chronic disease. Effective Clinical Practice4(6): 256–262.
44.
MarksR (2014) Self-efficacy and arthritis disability: An updated synthesis of the evidence base and its relevance to optimal patient care. Health Psychology Open1(1): 2055102914564582.
45.
MarroquinB (2011) Interpersonal emotion regulation as a mechanism of social support in depression. Clinical Psychology Review31: 1276–1290.
46.
MarroquinBNolen-HoeksemaS (2015) Emotion regulation and depressive symptoms: Close relationships as social context and influence. Journal of Personality and Social Psychology109: 836.
47.
Martin-SuberoMAndersonGKanchanatawanB, et al. (2016) Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut–brain pathways. CNS Spectrums21(2): 184–198.
48.
MasiCMChenH-YHawkleyLC, et al. (2011) A meta-analysis of interventions to reduce loneliness. Personality and Social Psychology Review15: 219–266.
49.
McEwenBGianarosPJ (2010) Central role of the brain in stress and adaptation: Links to socioeconomic status, health, and disease. Annals of the New York Academy of Sciences1186: 190.
50.
MillerAHRaisonCL (2016) The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nature Reviews Immunology16(1): 22.
51.
MolderingsGJBrettnerSHomannJ, et al. (2011) Mast cell activation disease: A concise practical guide for diagnostic workup and therapeutic options. Journal of Hematology & Oncology4: 10.
52.
MolinaYChoiSWCellaD, et al. (2013) The stigma scale for chronic illnesses 8-item version (SSCI-8): Development, validation and use across neurological conditions. International Journal of Behavioral Medicine20: 450–460.
53.
MouraDSSultanSGeorgin-LavialleS, et al. (2011) Depression in patients with mastocytosis: Prevalence, features and effects of masitinib therapy. PLoS One6: e26375.
54.
MouraDSSultanSGeorgin-LavialleS, et al. (2012) Evidence for cognitive impairment in mastocytosis: Prevalence, features and correlations to depression. PLoS One7: e39468.
55.
Nicoloro-SantaBarbaraJLobelMWolfeD (2017) Psychosocial impact of mast cell disorders: Pilot investigation of a rare and understudied disease. Journal of Health Psychology22: 1277–1288.
56.
Nicoloro-SantaBarbaraJ (2019) Emotional distress, resilience, and physical health in people with rare and non-rare chronic disease. Doctoral dissertation, State University of New York at Stony Brook.
57.
ParadaPOlivaMLázaroE, et al. (2014) Anxiety, depression and self-efficacy in patients with Myasthenia Gravis. International Journal of Psychology and Psychological Therapy14: 105–113.
58.
PicardMGiavina-BianchiPMezzanoV, et al. (2013) Expanding spectrum of mast cell activation disorders: Monoclonal and idiopathic mast cell activation syndromes. Clinical Therapeutics35: 548–562.
59.
RadloffL (1977) The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement1: 385–401.
60.
RogersMPBloomingdaleKMurawskiBJ, et al. (1986) Mixed organic brain syndrome as a manifestations of systemic mastocytosis. Psychosomatic Medicine48(6): 437–447.
61.
RussellDPeplauLACutronaCE (1980) The revised UCLA Loneliness Scale: Concurrent and discriminant validity evidence. Journal of Personality and Social Psychology39: 472–480.
62.
ScheierMECarverCS (1987) Dispositional optimism and physical well-being: The influence of generalized outcome expectancies on health. Journal of Personality55: 169–210.
63.
ScheierMFCarverCSBridgesMW (1994) Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): A reevaluation of the Life Orientation Test. Journal of Personality and Social Psychology67(6): 1063–1078.
64.
SchouIEkebergØRulandC (2005) The mediating role of appraisal and coping in the relationship between optimism-pessimism and quality of life. Psycho-Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer14: 718–727.
65.
SherbourneCDStewartAL (1991) The MOS social support survey. Social Science & Medicine32(6): 705–714.
66.
SiebenhaarFvon TschirnhausEHartmannK, et al. (2016) Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy71: 869–877.
67.
SiroisFMWoodAM (2017) Gratitude uniquely predicts lower depression in chronic illness populations: A longitudinal study of inflammatory bowel disease and arthritis. Health Psychology36: 122.
68.
SlavichGMIrwinMR (2014) From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. Psychological Bulletin140(3): 774.
69.
StantonALRevensonTATennenH (2007) Health psychology: Psychological adjustment to chronic disease. Annual Review of Psychology58: 565–592.
70.
SteptoeAWardleJMarmotM (2005) Positive affect and health-related neuroendocrine, cardiovascular, and inflammatory processes. Proceedings of the National Academy of Sciences102(18): 6508–6512.
TaftTHBallouSKeeferL (2013) A preliminary evaluation of internalized stigma and stigma resistance in inflammatory bowel disease. Journal of Health Psychology18: 451–460.
73.
TheoharidesTCKonstantinidouAD (2007) Corticotropin-releasing hormone and the blood-brain-barrier. Frontiers in Bioscience12: 1615–1628.
74.
TheoharidesTCValentPAkinC (2015) Mast cells, mastocytosis, and related disorders. New England Journal of Medicine373: 163–172.
75.
ThompsonTPérezMKreuterM, et al. (2017) Perceived social support in African American breast cancer patients: Predictors and effects. Social Science & Medicine192: 134–142.
ValentPAkinC (2019) Doctor, I think I am suffering from MCAS: Differential diagnosis and separating facts from fiction. The Journal of Allergy and Clinical Immunology: In Practice7: 1109–1114.
78.
ValentPAkinCArockM, et al. (2012) Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal. International Archives of Allergy and Immunology157: 215–225.
79.
ValentPAkinCBonadonnaP, et al. (2018) Mast cell activation syndrome: Importance of consensus criteria and call for research. Journal of Allergy and Clinical Immunology142: 1008–1010.
80.
VermeirenMRKranenburgLWvan DaelePL, et al. (2020) Psychological functioning and quality of life in patients with mastocytosis: A cross-sectional study. Annals of Allergy, Asthma & Immunology124: 373–378.e372.
81.
von der LippeCDiesenPSFeragenKB (2017) Living with a rare disorder: A systematic review of the qualitative literature. Molecular Genetics & Genomic Medicine5: 758–773.
82.
WästfeltMFadeelBHenterJ-I (2006) A journey of hope: Lessons learned from studies on rare diseases and orphan drugs. Journal of Internal Medicine260(1): 1–10.
83.
WeinertCCudneySHillWG (2008) Rural women, technology, and self-management of chronic illness. The Canadian Journal of Nursing Research= Revue canadienne de recherche en sciences infirmieres40(3): 114.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
